RANDOMIZED, DOUBLE-BLIND, PHASE II STUDY OF RUXOLITINIB OR PLACEBO IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH METASTATIC PANCREATIC CANCER FOR WHOM THERAPY WITH GEMCITABINE HAD FAILED